Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential

SLS009Positive

AI Analysis

Summary

Alliance Global analyst reports that Sellas' experimental CDK9 inhibitor SLS009 appears to be leading in its competitive class, with the analyst identifying approximately 200% upside potential for the company.

Importance:5/10

Sentiment:

0.65

CDK9 inhibitoranalyst commentarycompetitive positioningprice target

Related Companies

$LITS

Read the original article

Published by yahoo_finance on August 12, 2026 4:07 PM

Read Original